Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.82 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.82 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.82 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.82 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.82 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mrk-560 SCHEMBL237759 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL29358202 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237758 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237760 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8257641 | 0.89 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8255255 | 0.88 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8339487 | 0.88 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8255159 | 0.88 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8246606 | 0.87 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8342639 | 0.87 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551799-B1 | CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | MERCK SHARP & DOHME LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | MERCK SHARP & DOHME LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| WO-2006123184-A2 | SULPHONAMIDO-SUBSTITUTED CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | SDHA, SDHB, TP53 | PSEN1 2352/4885PSEN2 2663/4885APH1B 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.